keyword
MENU ▼
Read by QxMD icon Read
search

valganciclovir

keyword
https://www.readbyqxmd.com/read/29028114/trichodysplasia-spinulosa-associated-with-hiv-infection-clinical-response-to-acitretin-and-valganciclovir
#1
M Aleissa, M P Konstantinou, M Samimi, L Lamant, P Gaboriaud, A Touze, C Ceppi, C Bulai Livideanu, C Paul
No abstract text is available yet for this article.
October 13, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29021960/relapsing-ebv-encephalitis-in-a-renal-transplant-recipient
#2
Joshua A Stone, Bettina M Knoll, Dimitrios Farmakiotis
In solid organ transplant recipients, Epstein-Barr virus (EBV) can cause active central nervous system (CNS) infection or malignant transformation of latently infected cells in the CNS, known as post-transplant lymphoproliferative disease (PTLD). Reduction of T-cell immunosuppression is the cornerstone of management. The role of antivirals with in-vitro activity against herpesviruses in EBV-related CNS syndromes is controversial, as they have no effect on latent virus. We report an unusual case of relapsing EBV encephalitis in a donor-positive, EBV-negative renal transplant recipient, with response to valganciclovir...
2017: IDCases
https://www.readbyqxmd.com/read/29020220/role-of-secondary-prophylaxis-with-valganciclovir-in-the-prevention-of-recurrent-cytomegalovirus-disease-in-solid-organ-transplant-recipients
#3
Bradley J Gardiner, Jennifer K Chow, Lori Lyn Price, Natalie E Nierenberg, David M Kent, David R Snydman
Background: Cytomegalovirus (CMV) is a major contributor to morbidity and mortality in solid organ transplant recipients (SOTR). Ganciclovir and valganciclovir are highly effective antiviral drugs whose role in primary prophylaxis and treatment of CMV disease is well established. The objective of this study was to examine the effect of secondary prophylaxis (SP) on the risk of relapse in SOTR following an episode of CMV disease. Methods: We performed a retrospective cohort study of SOTR from 1995-2015 and used propensity score based inverse probability of treatment weighting methodology to control for confounding by indication...
August 7, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28986189/prevention-of-cmv-reactivation-in-haploidentical-stem-cell-transplantation
#4
Aimee E Hammerstrom, Lindsey R Lombardi, Sai Ravi Pingali, Gabriela Rondon, Julianne Chen, Denái R Milton, Roy F Chemaly, Richard E Champlin, Alison Gulbis, Stefan O Ciurea
Cytomegalovirus (CMV) infection can increase the morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Due to a higher degree of immunosuppression, haploidentical transplant recipients may be at an increased risk of viral infections, particularly CMV. We retrospectively analyzed 86 haploidentical HCT recipients at our institution, to determine whether a more intensified antiviral strategy would reduce the incidence of CMV reactivation compared with a traditional antiviral prophylaxis regimen...
October 3, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28940831/low-dose-valganciclovir-prophylaxis-for-cytomegalovirus-in-intermediate-risk-r-renal-transplant-recipients-single-center-experience
#5
Salman Khan, Clara Fischman, Shirish Huprikar
Renal transplant recipients (RTR) who are seropositive for CMV (R+) are considered to be at intermediate-risk for CMV disease. Current guidelines recommend high-dose valganciclovir (VGCV) prophylaxis because of limited data on the efficacy of low-dose VGCV. We describe our experience with using low-dose VGCV in R+ RTR. We retrospectively reviewed a cohort of 316 R+ RTR at our institution between 2002 and 2006. The primary endpoint was CMV disease at 1 year post transplant. The incidence of CMV disease at 12 months after transplantation was only 3% (6/221) in the D+R+ and 4% (4/95) in the D-R+ RTR...
September 22, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28937523/cytomegalovirus-retinitis-associated-with-occlusive-vasculopathy-in-an-elderly-human-immunodeficiency-virus-negative-man
#6
Kareem Moussa, Thuy Doan, Jay M Stewart, Jessica Shantha, John Gonzales, Nisha Acharya, Emmett T Cunningham
PURPOSE: To present a case of cytomegalovirus (CMV) retinitis associated with occlusive vasculopathy presenting as sudden unilateral loss of vision in a human immunodeficiency virus-negative elderly man. METHODS: Clinical case report and literature review. RESULTS: An 84-year-old Chinese man with diabetes mellitus and primary open-angle glaucoma was seen in consultation by our uveitis service for evaluation of sudden vision loss in the right eye...
September 20, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/28937438/cutaneous-cytomegalovirus-infection-in-an-immunocompetent-patient-innocent-bystander-or-culprit
#7
Solomiya Grushchak, Kelli A Hutchens, Cossette Joy, Anthony Peterson, Jodi Speiser, Kumaran Mudaliar
We present a rare case of cutaneous cytomegalovirus (CMV) infection in a nonimmunocompromised patient. A 74-year-old woman with a history of diabetes presented with an ulcer on the right lateral tibia that occurred at the site of a nerve core biopsy. Subsequent biopsy of the ulcer edge showed granulation tissue with neutrophilic inflammation. The patient underwent extensive antibiotic treatment for possible infection with weekly wound care. However, the ulceration persisted and enlarged. A repeat biopsy 1 year later showed superficial and deep mixed inflammation with an associated vasculitis...
September 11, 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/28921781/valganciclovir-vgcv-followed-by-cytomegalovirus-cmv-hyperimmune-globulin-compared-to-vgcv-for-200-days-in-abdominal-organ-transplant-recipients-at-high-risk-for-cmv-infection-a-prospective-randomized-pilot-study
#8
James N Fleming, David J Taber, Nicole A Weimert, Satish Nadig, John W McGillicuddy, Charles F Bratton, Prabhakar K Baliga, Kenneth D Chavin
BACKGROUND: With the advent of effective antivirals against cytomegalovirus (CMV), use of CMV hyperimmune globulin has decreased. Although antiviral prophylaxis in patients at high risk for CMV is effective, many patients still have late infection, never developing antibodies sufficient to achieve immunity. Utilizing a combination of antiviral and CMV immunoglobulin G may allow patients to achieve immunity and decrease late CMV infections. METHODS: This was a prospective randomized, open-label, pilot study comparing valganciclovir (VGCV) prophylaxis for 200 days vs VGCV for 100 days followed by CMV HIG in abdominal transplant recipients at high risk for CMV...
September 16, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28862190/seroprevalence-of-cytomegalovirus-in-donors-opportunistic-viral-infections-in-liver-transplant-recipients
#9
Joy Varghese, S Subramanian, Mettu Srinivas Reddy, Naresh Shanmugam, G Balajee, Vijaya Srinivasan, Jayanthi Venkataraman, Rela Mohamed
BACKGROUND & OBJECTIVES: Opportunistic virus infections are common in liver transplant (LT) recipients. There is a risk of developing infection with cytomegalovirus (CMV) and herpes-related viruses such as herpes simplex virus-1 and 2 (HSV-1 & 2), Epstein-Barr virus (EBV) and Varicella Zoster virus (VZV), reactivation of infection and recurrent infection. This study was conducted to determine CMV seropositivity in donors and its influence on LT recipients and seropositivity of CMV, HSV-1 and 2, EB viral capsid antigen (EBVCA) and VZV in LT recipients and their reactivation...
April 2017: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/28844151/high-dose-acyclovir-for-cytomegalovirus-prophylaxis-in-seropositive-abdominal-transplant-recipients
#10
Margaret R Jorgenson, Jillian L Descourouez, Glen E Leverson, Erin K McCreary, Michael R Lucey, Jeannina A Smith, Robert R Redfield
BACKGROUND: Following abdominal solid organ transplant (aSOT), valganciclovir (VGC) is recommended for cytomegalovirus (CMV) prophylaxis. This agent is associated with efficacy concerns, toxicity, and emergence of ganciclovir resistance. OBJECTIVE: To evaluate the incidence of high-dose acyclovir (HD-A) prophylaxis failure in seropositive aSOT recipients (R+). METHODS: This was a retrospective, single-center study of R+ transplanted without lymphocyte-depleting induction between January 1, 2000, and June 30, 2013, discharged with 3 months of HD-A prophylaxis (800 mg 4 times daily)...
August 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28838440/ganciclovir-dosing-strategies-and-development-of-cytomegalovirus-resistance-in-a-kidney-transplant-recipient-a-case-report
#11
I A Echenique, D Beltran, L Ramirez-Ruiz, N Najafian, N Agrawal
In renal transplant recipients, delayed graft function and accompanying renal impairment may lead to therapeutic underexposure of valganciclovir. We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance. Assessments and adjustments for renal dysfunction, according to both Cockgroft-Gault and Modification of Diet in Renal Disease study equations, are described...
September 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28838145/valganciclovir-for-the-suppression-of-epstein-barr-virus-replication
#12
RANDOMIZED CONTROLLED TRIAL
Jessica E Yager, Amalia S Magaret, Steven R Kuntz, Stacy Selke, Meei-Li Huang, Lawrence Corey, Corey Casper, Anna Wald
Epstein-Barr virus (EBV) causes infectious mononucleosis and can lead to lymphoproliferative diseases. We evaluated the effects of valganciclovir on oral EBV shedding in a randomized, double-blind, placebo-controlled study. Twenty-six men received oral valganciclovir or daily placebo for 8 weeks, followed by a 2-week "washout period" and then 8 weeks of the alternative treatment. Valganciclovir reduced the proportion of days with EBV detected from 61.3% to 17.8% (relative risk, 0.28; 95% confidence interval [CI], ...
July 15, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28830465/emerging-val-ganciclovir-resistance-during-treatment-of-congenital-cmv-infection-a-case-report-and-review-of-the-literature
#13
Beatriz Morillo-Gutierrez, Sheila Waugh, Ailsa Pickering, Terence Flood, Marieke Emonts
BACKGROUND: Congenital cytomegalovirus (cCMV) infection is an important illness that is a common cause of hearing loss in newborn infants and a major cause of disability in children. For that reason, treatment of symptomatic patients with either ganciclovir or its pro-drug valganciclovir is recommended. Treatment duration of 6 months has been shown to be more beneficial than shorter courses; however, there is uncertainty regarding emergence of resistance strains, secondary effects and long term sequelae...
August 22, 2017: BMC Pediatrics
https://www.readbyqxmd.com/read/28829877/effect-of-ganciclovir-on-il-6-levels-among-cytomegalovirus-seropositive-adults-with-critical-illness-a-randomized-clinical-trial
#14
RANDOMIZED CONTROLLED TRIAL
Ajit P Limaye, Renee D Stapleton, Lili Peng, Scott R Gunn, Louise E Kimball, Robert Hyzy, Matthew C Exline, D Clark Files, Peter E Morris, Stephen K Frankel, Mark E Mikkelsen, Duncan Hite, Kyle B Enfield, Jay Steingrub, James O'Brien, Polly E Parsons, Joseph Cuschieri, Richard G Wunderink, David L Hotchkin, Ying Q Chen, Gordon D Rubenfeld, Michael Boeckh
Importance: The role of cytomegalovirus (CMV) reactivation in mediating adverse clinical outcomes in nonimmunosuppressed adults with critical illness is unknown. Objective: To determine whether ganciclovir prophylaxis reduces plasma interleukin 6 (IL-6) levels in CMV-seropositive adults who are critically ill. Design, Setting, and Participants: Double-blind, placebo-controlled, randomized clinical trial (conducted March 10, 2011-April 29, 2016) with a follow-up of 180 days (November 10, 2016) that included 160 CMV-seropositive adults with either sepsis or trauma and respiratory failure at 14 university intensive care units (ICUs) across the United States...
August 22, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28827083/combination-therapy-with-brincidofovir-and-valganciclovir-against-species-c-adenovirus-infection-in-the-immunosuppressed-syrian-hamster-model-allows-for-substantial-reduction-of-dose-for-both-compounds
#15
Karoly Toth, Ann E Tollefson, Jacqueline F Spencer, Baoling Ying, William S M Wold
Adenovirus infections of immunocompetent adults are usually mild and resolve without serious sequelae. However, adenovirus infections of immunocompromised patients often develop into life-threatening multi-organ disease. Pediatric hematopoietic transplant patients are especially threatened, with high incidence of infection and high mortality rates. Presently, there is no drug specifically approved by the FDA to treat adenovirus infections; thus there is an urgent need to develop effective antivirals against the virus...
August 4, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28822107/successful-treatment-and-fdg-pet-ct-monitoring-of-hhv-6-encephalitis-in-a-non-neutropenic-patient-case-report-and-literature-review
#16
Elda Righi, Alessia Carnelutti, Daniele Muser, Francesco Zaja, Elisa Lucchini, Federico Pea, Fernando Di Gregorio, Abass Alavi, Matteo Bassetti
Human herpesvirus (HHV)-6 reactivation is associated with severe forms of encephalitis among patients undergoing hematopoietic stem cell transplantation. Cases in non-neutropenic patients are uncommon. The efficacy of ganciclovir and other compounds that are used for the treatment of HHV-6 encephalitis remains suboptimal and linked to toxicity. Valganciclovir, the oral prodrug of ganciclovir, could be practical to treat outpatients, but it is not commonly used for severe cases. We report a case of HHV-6 encephalitis in a non-neutropenic patient successfully treated with valganciclovir and undergoing therapeutic drug monitoring in plasma and in the cerebrospinal fluid...
August 18, 2017: Journal of Neurovirology
https://www.readbyqxmd.com/read/28781310/severe-thrombocytopenia-during-dolutegravir-containing-antiretroviral-therapy
#17
Kazuhiko Nakaharai, Makiko Miyajima, Hiroaki Kobayashi, Akihiro Shimizu, Yumiko Hosaka, Tetsuya Horino, Seiji Hori
A 56-year-old Japanese man diagnosed with acquired immunodeficiency syndrome, Pneumocystis jirovecii pneumonia and cytomegalovirus infection presented with thrombocytopenia after starting antiretroviral therapy, which included dolutegravir (DTG). Although good control of the human immunodeficiency virus and cytomegalovirus infections was achieved, the patient's thrombocytopenia persisted. The patient's platelet count decreased to ≤50,000/μL even after the cessation of valganciclovir, which can cause bone marrow suppression...
August 15, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28736953/neutropenia-in-kidney-and-liver-transplant-recipients-risk-factors-and-outcomes
#18
Thomas A Mavrakanas, Marie-Andrée Fournier, Sarah Clairoux, Jacques-Alexandre Amiel, Marie-Eve Tremblay, Donald C Vinh, Christian Coursol, Daniel J G Thirion, Marcelo Cantarovich
No studies have directly compared the key characteristics and outcomes of kidney (KTx) and liver transplantation (LTx) recipients with neutropenia. In this single-center, retrospective, cohort study, we enrolled all adult patients who received a KTx or LTx between 2000 and 2011. Neutropenia was defined as 2 consecutive absolute neutrophil count (ANC) values <1500/mm(3) in patients without preexisting neutropenia. The first neutropenia episode occurring during the first year post-transplantation was analyzed...
July 24, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28734808/-congenital-cytomegalovirus-infection-manifesting-as-neonatal-respiratory-distress-in-an-hiv-exposed-uninfected-newborn
#19
A Pham, H El Mjati, N Nathan, F Kieffer, D Mitanchez
BACKGROUND: Cytomegalovirus (CMV) is one of the most common intrauterine infections, affecting approximately 1% of all live births. There are few reports on congenital CMV infections manifesting as isolated pneumonitis. CASE REPORT: We report a case of congenital CMV with neonatal respiratory distress affecting an HIV-exposed uninfected infant. This infant required noninvasive ventilation beginning within the first 15min of life. The initial chest X-ray showed diffuse bilateral ground-glass opacifications...
July 19, 2017: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://www.readbyqxmd.com/read/28733760/intrauterine-therapy-of-cytomegalovirus-infection-with-valganciclovir-review-of-the-literature
#20
REVIEW
Vera Seidel, Cornelia Feiterna-Sperling, Jan-Peter Siedentopf, Jörg Hofmann, Wolfgang Henrich, Christoph Bührer, Katharina Weizsäcker
Congenital cytomegalovirus (CMV) infection is the leading cause for sensorineural hearing loss and mental retardation in children without genetic diseases worldwide. There is little evidence guiding therapeutic strategies during pregnancy when intrauterine fetal CMV infection is confirmed. We provide a systematic review of the use of ganciclovir (GCV) or VGCV during pregnancy discussing safety of its use for mother and fetus and describe two cases of intrauterine therapy of fetal CMV infection with valganciclovir (VGCV)...
July 21, 2017: Medical Microbiology and Immunology
keyword
keyword
38260
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"